NASDAQ: VYNEVyne Therapeutics Inc Stock
$0.64+0.01 (+1.59%)
Updated Jun 18, 2026
VYNE Price
$0.64
Fair Value Price
$0.48
Market Cap
$21.18M
52 Week Low
$0.28
52 Week High
$1.96
P/E
-1.3x
P/B
0.86x
P/S
56.26x
PEG
N/A
Dividend Yield
N/A
Revenue
$454.00k
Earnings
-$21.46M
Gross Margin
100%
Operating Margin
-4,725.33%
Profit Margin
-4,726.2%
Debt to Equity
0.05
Operating Cash Flow
-$26M
Beta
1.02
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
VYNE Overview
VYNE Therapeutics Inc. is a pharmaceutical enterprise dedicated to discovering and advancing therapies for immune-mediated inflammatory conditions. Its development portfolio features FCD105, a topical foam formulation that has successfully finished Phase III clinical studies for the management of moderate-to-severe acne vulgaris. Another candidate in its pipeline is FMX114, a combination treatment incorporating tofacitinib, which is currently in early-stage clinical assessment, referred to as a Phase IIa preclinical trial, for addressing mild-to-moderate atopic dermatitis. Additionally, the company is progressing VYN201, a bromodomain and extra-terminal (BET) inhibitor designed to target a range of immuno-inflammatory disorders, notably those affecting the skin. A further asset is VYN202, which comprises BET inhibitor compounds engineered for selective action on bromodomain 2. Established in 2003, the firm was formerly recognized as Menlo Therapeutics Inc. before officially changing its corporate identity to VYNE Therapeutics Inc. in September 2020. The company's principal operations are based in Bridgewater, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VYNE's potential to beat the market
- VYNE doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
VYNE
RankedUnranked of 465
RankedUnranked of 465
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $224.66 | A | |
| $51.91 | A | |
| $16.46 | A |
Be the first to know about important VYNE news, forecast changes, insider trades & much more!
VYNE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VYNE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VYNE ($0.64) is overvalued by 32.96% relative to our estimate of its Fair Value price of $0.48 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
VYNE ($0.64) is not significantly undervalued (32.96%) relative to our estimate of its Fair Value price of $0.48 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
VYNE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VYNE due diligence checks available for Premium users.
Valuation
VYNE fair value
Fair Value of VYNE stock based on Discounted Cash Flow (DCF)
Price
$0.64
Fair Value
$0.48
Overvalued by
34.01%
VYNE ($0.64) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VYNE ($0.64) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VYNE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
VYNE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.3x
Industry
15.77x
Market
9.47x
VYNE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.86x
Industry
4.95x
VYNE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
VYNE's financial health
Profit margin
Revenue
$86.0k
Net Income
-$3.6M
Profit Margin
-4,168.6%
VYNE's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
VYNE's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$25.9M
Liabilities
$1.2M
Debt to equity
0.05
VYNE's short-term assets ($25.79M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VYNE's short-term assets ($25.79M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VYNE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VYNE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.1M
Investing
$4.7M
Financing
-$15.0k
VYNE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
VYNE vs Biotech Stocks
Vyne Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.